{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Larimar Therapeutics, Inc.
Is Larimar Therapeutics, Inc. technically bullish or bearish?
As of May 27, 2025, the technical trend is mildly bearish, influenced by daily moving averages and weekly Bollinger Bands indicating bearish signals, despite mixed signals from the MACD and some mild bullishness in the KST and Dow Theory.
Who are in the management team of Larimar Therapeutics, Inc.?
As of March 2022, the management team of Larimar Therapeutics, Inc. includes Mr. Joseph Truitt (Chairman), Dr. Carole Ben-Maimon (President and CEO), and Board members Mr. Thomas Hamilton, Mr. Jonathan Leff, Dr. Thomas Daniel, and Mr. Frank Thomas.
What does Larimar Therapeutics, Inc. do?
Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases using cell penetrating peptide technology. It has a market cap of $172.24 million and reported a net profit loss of $29 million as of March 2025.
How big is Larimar Therapeutics, Inc.?
As of Jun 18, Larimar Therapeutics, Inc. has a market capitalization of 172.24 million, with net sales of 0.00 million and a net profit of -95.23 million over the latest four quarters. The company reported shareholder's funds of 171.81 million and total assets of 200.93 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
